Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

tradersunion353 Apr. 23 at 10:12 PM

$ABCL Until the postive talk and hype reflects in share price.. this is POS performance Keep pumping and day dreaming

1 · Reply

8008track Apr. 23 at 8:28 PM

$ABCL one day closer to the inevitable phase 2 readout of 635

0 · Reply

DeMampCamp Apr. 23 at 5:37 PM

$ABCL Indexes fell off a cliff, giving people a great opportunity here to load a nice dip

0 · Reply

Art_BunyaaHa Apr. 23 at 5:32 PM

$ABCL adding calls here

0 · Reply

Targhee Apr. 23 at 5:29 PM

$ABCL 👀…you’re killing me, smalls!

0 · Reply

tradersunion353 Apr. 23 at 5:20 PM

$ABCL who are married to this stock can now load and add shares.. 🤣 As the stock dropped now. cheerleaders will start getting high

0 · Reply

VIXHunter0 Apr. 23 at 4:15 PM

$ABCL is basically sitting right on the 200-day moving average, a key battleground level. Price has tested it multiple times without a decisive break or rejection, showing a clear tug-of-war between bulls and bears. 👉If this is helpful to you, tap @VIXHunter0

0 · Reply

tradersunion353 Apr. 23 at 4:01 PM

$ABCL Overhyped underperforming POS true torture for long term investors long tem investors = who have been holding for 2-3 years. Not applicable here for who are married to this stock.

0 · Reply

sogenerous Apr. 23 at 3:14 PM

$ABCL little weaker than I expected on day 2 of 200D test so de-risking shares that went to LTCG +101K into ER/Data here 2 with 2 weeks to go into ER

2 · Reply

hagarone Apr. 23 at 2:42 PM

$ABCL Doubled position. Let’s go

0 · Reply

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026, 4:05 PM EDT - 22 days ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Feb 24, 2026, 4:05 PM EST - 2 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 3 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 12, 2026, 9:00 AM EST - 3 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 4 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 4 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Nov 10, 2025, 9:00 AM EST - 5 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 4:05 PM EST - 6 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 8 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 8 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 4:05 PM EDT - 9 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Feb 23, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Resignation of Board Member

tradersunion353 Apr. 23 at 10:12 PM

$ABCL Until the postive talk and hype reflects in share price.. this is POS performance Keep pumping and day dreaming

1 · Reply

8008track Apr. 23 at 8:28 PM

$ABCL one day closer to the inevitable phase 2 readout of 635

0 · Reply

DeMampCamp Apr. 23 at 5:37 PM

$ABCL Indexes fell off a cliff, giving people a great opportunity here to load a nice dip

0 · Reply

Art_BunyaaHa Apr. 23 at 5:32 PM

$ABCL adding calls here

0 · Reply

Targhee Apr. 23 at 5:29 PM

$ABCL 👀…you’re killing me, smalls!

0 · Reply

tradersunion353 Apr. 23 at 5:20 PM

$ABCL who are married to this stock can now load and add shares.. 🤣 As the stock dropped now. cheerleaders will start getting high

0 · Reply

VIXHunter0 Apr. 23 at 4:15 PM

0 · Reply

tradersunion353 Apr. 23 at 4:01 PM

$ABCL Overhyped underperforming POS true torture for long term investors long tem investors = who have been holding for 2-3 years. Not applicable here for who are married to this stock.

0 · Reply

sogenerous Apr. 23 at 3:14 PM

$ABCL little weaker than I expected on day 2 of 200D test so de-risking shares that went to LTCG +101K into ER/Data here 2 with 2 weeks to go into ER

2 · Reply

hagarone Apr. 23 at 2:42 PM

$ABCL Doubled position. Let’s go

0 · Reply

UncleTomFlorida Apr. 23 at 2:32 PM

$ABCL Short Volume

1 · Reply

UncleTomFlorida Apr. 23 at 2:27 PM

$ABCL The shorts will try to protect their positions by hammering it down. Same with $IRBX. Ultimately, the facts of great management should prevail over the naysayers.

2 · Reply

DeMampCamp Apr. 23 at 2:01 PM

$ABCL Man, if the company just had one freaking PR, I've been screaming about this for years! They can NEVER be blamed for pump and dumps, that's for damn sure! But come on, get crafty, do something unexpected, get your damn share price up BEFORE the read outs during ER!! Carl is awesome, IR not so much!

1 · Reply

FonsieTrader Apr. 23 at 1:45 PM

$ABCL 👀 This one is flying under the radar… → Short Float: ~21% → Days to Cover: 18.7 (!!) That’s not a fast squeeze… that’s pressure building over time Now add this: → Price reclaiming key levels → Momentum turning → Volume picking up If this continues, shorts don’t exit fast here… they get squeezed slowly Disclaimer: Not financial advice. Do your own research.

0 · Reply

UncleTomFlorida Apr. 23 at 1:44 PM

$ABCL Popped this morning - freaky awesome❣️

1 · Reply

UncleTomFlorida Apr. 23 at 1:44 PM

$ABCL

0 · Reply

sogenerous Apr. 23 at 1:39 PM

$ABCL 👀

0 · Reply

snowPOW Apr. 23 at 2:55 AM

$ABCL https://www.canada.ca/en/innovation-science-economic-development/news/2026/04/canada-launches-national-initiative-to-build-large-scale-ai-supercomputing-capacity.html Fits for many reasons. Could have cash on the way.

0 · Reply

UncleTomFlorida Apr. 22 at 10:09 PM

$ABCL https://x.com/JackPrescottX/status/2047021905178145212?s=20

1 · Reply

SteveJohnsonis Apr. 22 at 9:48 PM

$ABCL

0 · Reply

backtesttrend Apr. 22 at 8:34 PM

$ABCL weekly structure update: still trading within a broader consolidation range. Price action continues to compress around key mid-term moving averages, with volatility contracting and volume gradually fading but stable. Overhead weekly resistance remains intact with no confirmed breakout, while lower structural support continues to hold. The next key trigger is a weekly breakout with volume expansion, which could shift price into a trend continuation phase; otherwise, expect ongoing range-bound consolidation and structural repair. 👉If this helps, tap @backtesttrend

0 · Reply

snowPOW Apr. 22 at 8:23 PM

$ABCL up over 75% yoy Not bad

0 · Reply

Market Cap	1.21B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	8,150,800
Avg Vol	3,186,172
Day's Range	N/A - N/A
Shares Out	303.16M
Stochastic %K	82%
Beta	0.85
Analysts	Strong Sell
Price Target	$9.43